Relevant bibliographies by topics / Targeted alpha therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Targeted alpha therapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Targeted alpha therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Targeted alpha therapy"

1

HANAOKA, Hironari, and Tsutomu TAKEUCHI. "Interferon ^|^alpha;-targeted therapy." Japanese Journal of Clinical Immunology 36, no. 4 (2013): 181–88. http://dx.doi.org/10.2177/jsci.36.181.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zalutsky, M. R., and G. Vaidyanathan. "383 TARGETED ALPHA THERAPY." Radiotherapy and Oncology 102 (March 2012): S195. http://dx.doi.org/10.1016/s0167-8140(12)70332-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kozempel, Jan, and Martin Vlk. "Nanoconstructs in Targeted Alpha-Therapy." Recent Patents on Nanomedicine 4, no. 2 (March 11, 2015): 71–76. http://dx.doi.org/10.2174/1877912305666150102000549.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Morgenstern, Alfred, Frank Bruchertseifer, and Christos Apostolidis. "Targeted Alpha Therapy with 213Bi." Current Radiopharmaceuticalse 4, no. 4 (October 1, 2011): 295–305. http://dx.doi.org/10.2174/1874471011104040295.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Majkowska-Pilip, Agnieszka, Weronika Gawęda, Kinga Żelechowska-Matysiak, Kamil Wawrowicz, and Aleksander Bilewicz. "Nanoparticles in Targeted Alpha Therapy." Nanomaterials 10, no. 7 (July 13, 2020): 1366. http://dx.doi.org/10.3390/nano10071366.

Full text
Abstract:
Recent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery. In this publication, we provide a comprehensive overview of available information on functional nanomaterials for targeted alpha therapy. The first section describes why nanoconstructs are used for the synthesis of α-emitting radiopharmaceuticals. Next, we present the synthesis and summarise the rec
APA, Harvard, Vancouver, ISO, and other styles
6

Vaidyanathan, Ganesan, and Michael R. Zalutsky. "Targeted therapy using alpha emitters." Physics in Medicine and Biology 41, no. 10 (October 1, 1996): 1915–31. http://dx.doi.org/10.1088/0031-9155/41/10/005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Allen, Barry J., Chand Raja, Syed Rizvi, Yong Li, Wendy Tsui, David Zhang, Emma Song, et al. "Targeted alpha therapy for cancer." Physics in Medicine and Biology 49, no. 16 (July 31, 2004): 3703–12. http://dx.doi.org/10.1088/0031-9155/49/16/016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sgouros, George. "Alpha-particles for targeted therapy." Advanced Drug Delivery Reviews 60, no. 12 (September 2008): 1402–6. http://dx.doi.org/10.1016/j.addr.2008.04.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Morgenstern, A., K. Abbas, F. Bruchertseifer, and C. Apostolidis. "Production of Alpha Emitters for Targeted Alpha Therapy." Current Radiopharmaceuticalse 1, no. 3 (September 1, 2008): 135–43. http://dx.doi.org/10.2174/1874471010801030135.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

J. Allen, Barry. "Future Prospects for Targeted Alpha Therapy." Current Radiopharmaceuticalse 4, no. 4 (October 1, 2011): 336–42. http://dx.doi.org/10.2174/1874471011104040336.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Targeted alpha therapy"

1

Song, Emma Yanjun Clinical School St George Hospital Faculty of Medicine UNSW. "Targeted alpha therapy for epithelial ovarian cancer." Awarded by:University of New South Wales. Clinical School - St George Hospital, 2007. http://handle.unsw.edu.au/1959.4/40874.

Full text
Abstract:
Purpose: Control of micrometastatic ovarian cancer in the peritoneal cavity remains a major objective in post-surgical treatment. The purpose of this project was to investigate the efficacy and toxicity of targeted alpha therapy (TAT) for ovarian cancer in vitro and in vivo in animal models and to select the optimal targeting vector for an ovarian cancer clinical trial. Animal models of ovarian, breast and prostate cancer were developed and for further TAT; a phase I melanoma clinical trial was supported, paving the way for an ovarian cancer clinical trial. Methods: The expression of the turn
APA, Harvard, Vancouver, ISO, and other styles
2

Andrews, Shannon. "FOLATE CONJUGATED DENDRIMERS FOR TARGETED ANTICANCER THERAPY." VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/3497.

Full text
Abstract:
Anticancer therapeutics are often limited to suboptimal doses due to their lack of selectivity for tumor cells and resultant damage to healthy tissue. These limitations motivated researchers to develop tumor-specific delivery systems for improved therapeutic efficacy and reduced unintended cytotoxicity. Polyamidoamine dendrimers offer an ideal platform for designing targeted therapeutics with tunable characteristics that optimize pharmacokinetic behavior and targeting specificity. Ligand conjugation to dendrimer provides the biochemical interaction necessary to activate tumor-specific receptor
APA, Harvard, Vancouver, ISO, and other styles
3

Pashaeinejad, Masoumeh Physics Faculty of Science UNSW. "Targeted alpha-therapy:cell survival determination in melanoma tumours using Monte Carlo calculations." Awarded by:University of New South Wales. Physics, 2006. http://handle.unsw.edu.au/1959.4/23996.

Full text
Abstract:
This study investigates the Monte Carlo calculations of cell survival in metastatic subcutaneous melanoma cancer tumours. To achieve this goal, a Monte Carlo program called SLAB.FOR was developed by Prof. David Charlton. The program randomly places alphas from 213Bi in the medium, which is a cancer cell sized micro dosimeter with a SiO2 converter on the top and Si as the sensitive volume. Then the Monte Carlo program calculates the energy deposited by alphas and their chord length and also the dose deposited in the sensitive volume. To be able to use this program, some information was taken fr
APA, Harvard, Vancouver, ISO, and other styles
4

Toro-Gonzalez, Miguel. "LANTHANIDE-BASED CORE-SHELL NANOPARTICLES AS MULTIFUNCTIONAL PLATFORMS FOR TARGETED RADIONUCLIDE THERAPY AND MULTIMODAL MOLECULAR IMAGING." VCU Scholars Compass, 2018. https://scholarscompass.vcu.edu/etd/5647.

Full text
Abstract:
Lanthanide phosphate (LnPO4) and lanthanide vanadate (LnVO4) nanoparticles (NPs) are promising platforms for theranostic applications because of their chemical stability, low solubility, low toxicity, and unique luminescence and magnetic properties. Motivated by the high radiation resistance and ability to host actinides of naturally occurring lanthanide-based compounds, LnPO4 and LnVO4 NPs were studied as radionuclide carriers for targeted radionuclide therapy using in vivoα-generators, 223Ra, 225Ac, and 227Th. The implementation of these radionuclides has shown potential for the treatment of
APA, Harvard, Vancouver, ISO, and other styles
5

Petitprin, Aurélie. "Le RAFT-RGD radiomarqué avec un émetteur °- comme nouvel agent de radiothérapie interne vectorisée." Thesis, Grenoble, 2013. http://www.theses.fr/2013GRENS002/document.

Full text
Abstract:
Le RAFT-RGD radiomarqué avec un émetteur β- comme nouvel agent de radiothérapie interne vectorisée. L'intégrine αvβ3 est fortement impliquée en oncogenèse à travers son rôle dans la néoangiogenèse tumorale, dans la prolifération et la survie des cellules cancéreuses et dans le processus métastatique. L'intégrine αvβ3 est exprimée faiblement dans la plupart des tissus. Par contre, elle est fortement exprimée par les cellules endothéliales activées lors de l'angiogenèse et par les cellules de nombreux types de cancers invasifs. Ces caractéristiques font de l'intégrine αvβ3 une excellente cible p
APA, Harvard, Vancouver, ISO, and other styles
6

Doligalski, Michael Lawrence. "Design and Development of Peptidomimetic Ligands for Targeting Radiopharmaceuticals, Imaging Probes, and Immunotherapeutics in Oncologic Disease." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6492.

Full text
Abstract:
Cancer is a leading cause of morbidity and mortality in the developed world. While much has been learned about these diseases in the last few decades, one of the main barriers to widespread advancement is the heterogeneity of cancer biology. A growing body of evidence supports the idea that certain protein receptors are overexpressed on the surface of tumor cells as compared to normal tissues. These extracellular biomarkers provide a unique opportunity to selectively target the tumor with both imaging and therapeutic modalities. The research in this dissertation focuses on targeting proteins o
APA, Harvard, Vancouver, ISO, and other styles
7

Fouinneteau, Romain. "Design and evaluation of astatoaryl compounds stabilized against dehalogenation in oxidizing media." Electronic Thesis or Diss., Nantes Université, 2024. http://www.theses.fr/2024NANU1032.

Full text
Abstract:
La thérapie interne vectorisée alpha est une stratégie émergente pour le traitement des cancers. Le radiohalogène astate-211 (t1/2 = 7,2h) est l'un des émetteurs alpha les plus prometteurs. Malgré des applications cliniques initiales encourageantes avec le N- [211At]succinimidylastatobenzoate ([211At]SAB) comme groupe prosthétique pour marquer les anticorps, les études in vivo ont montré que la liaison carbone-astate est insuffisamment stable et conduit à la libération d'astate dans l'organisme, ce qui peut nuire à l'efficacité et à la sécurité du patient. Néanmoins, des études récentes ont mo
APA, Harvard, Vancouver, ISO, and other styles
8

Kostova, Vesela. "Shiga toxin targeted strategy for chemotherapy and cancer immunotherapy application using copper-free « Click » chemistry." Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCB144.

Full text
Abstract:
Pas de résumé<br>Recently targeted therapies appeared as attractive alternatives to classical antitumoral treatments. The approach, developed on the concept of targeting drug to cancer cells, aims to spear normal tissues and decrease the side effects. This doctoral dissertation focuses on developing new anticancer targeted treatments in the field of chemotherapy and cancer immunotherapy by exploiting an original targeting moiety, the B subunit of Shiga toxin (STxB). Its specific properties, such as, recognition with its receptor Gb3 overexpressed in cancer cells or in antigen-presenting cells,
APA, Harvard, Vancouver, ISO, and other styles
9

Kannengießer, Stefanie [Verfasser], and Thomas [Akademischer Betreuer] Fanghänel. "Optimization of the Synthesis of Ac-225-labelled DOTA-Radioimmunoconjugates for Targeted Alpha Therapy, based on Investigations on the Complexation of Trivalent Actinides by DOTA / Stefanie Kannengießer ; Betreuer: Thomas Fanghänel." Heidelberg : Universitätsbibliothek Heidelberg, 2013. http://d-nb.info/1177148838/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Larouze, Alexandre. "Dosimétrie de radioéléments émetteurs alpha pour la radiothérapie interne vectorisée." Electronic Thesis or Diss., Bordeaux, 2024. http://www.theses.fr/2024BORD0061.

Full text
Abstract:
La radiothérapie interne vectorisée (RIV) est une technique de traitement du cancer en médecine nucléaire qui consiste à coupler un radionucléide à une molécule vectrice capable de cibler spécifiquement les cellules cancéreuses. Les radionucléides utilisés cliniquement sont majoritairement des émetteurs β− (177Lu,131I, 90Y) ; néanmoins, un émetteur α (223Ra) a récemment été approuvé pour le traitement du cancer de la prostate. L’objectif de cette thèse est de caractériser - par l’intermédiaire d’un code Monte Carlo à structure de trace nommé TILDA-V - les dépôts d’énergie induits par les radio
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Targeted alpha therapy"

1

Chŏn, Yang-suk. Chongyang ŭi sansŏnghwa e ŭihan HIF-1[alpha] kwabarhyŏn kijŏn kyumyŏng kwa saeroun hangam chʻiryo tʻaget ŭi palgul =: Mechanism of HIF-1[alpha] overexpression in acidified tumor and novel target for anticancer therapy. [Seoul]: Pogŏn Pokchibu, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rai, Samarpit, Zachariah G. Goldsmith, Michael E. Lipkin, and Glenn M. Preminger. Ureteric stones. Edited by John Reynard. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0026.

Full text
Abstract:
Acute renal colic is a common presentation to the emergency department. It is estimated that about 12% of men and 5% of women will have at least one symptomatic stone by the age of 70. Renal colic has an annual incidence 16 cases per 10,000 per year, and a lifetime incidence of 2–5%. In the year 2000, there were over 600,000 emergency room visits for urolithiasis listed as the primary diagnosis in the United States alone. In this chapter, acute pharmacologic management of patients diagnosed with ureteral stones will be outlined. The pharmacology and clinical efficacy for narcotic and non-narco
APA, Harvard, Vancouver, ISO, and other styles
3

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Madhumita Bhattacharyya. Gynaecological cancers. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0020_update_001.

Full text
Abstract:
Genitourinary cancers examines the malignancies arising in the kidney, ureter, bladder, prostate, testis, and penis. Renal cancer has high propensity for systemic spread, largely mediated by overexpression of vascular endothelial growth factor (VEGF). Treatments include surgery, immunotherapy, and targeted therapy. Wilms tumour, a childhood malignancy of the kidney, warrants specialist paediatric oncology management to provide expertise in its unique pathology, staging, and treatment, often with surgery and chemotherapy. Cancer of the bladder and ureters, another tobacco related cancer, may pr
APA, Harvard, Vancouver, ISO, and other styles
4

De Backer, Daniel, and Patrick Biston. Vasopressors in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0034.

Full text
Abstract:
Vasopressors are used in various shock states to correct hypotension, aiming at restoring or improving organ and tissue perfusion. Vasopressor therapy may be associated with excessive vasoconstriction, but also metabolic and other side-effects. Hence, the ideal target for arterial pressure remains undetermined. Adrenergic agents remain the most commonly used vasopressor agents. Adrenergic agents increase arterial pressure through stimulation of alpha-adrenergic receptors. The effects of the different adrenergic agents differ mostly due to variable associated beta-adrenergic effects. Epinephrin
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Targeted alpha therapy"

1

Mastren, Tara. "Targeted Alpha Therapy." In Rare Earth Elements and Actinides: Progress in Computational Science Applications, 277–83. Washington, DC: American Chemical Society, 2021. http://dx.doi.org/10.1021/bk-2021-1388.ch013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Guatelli, Susanna, David Bolst, and Eva Bezak. "Monte Carlo simulations for targeted alpha therapy." In Monte Carlo in Heavy Charged Particle Therapy, 215–27. Boca Raton: CRC Press, 2023. http://dx.doi.org/10.1201/9781003023920-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Seidl, Christof, and Reingard Senekowitsch-Schmidtke. "Targeted Alpha Particle Therapy of Peritoneal Carcinomas." In Therapeutic Nuclear Medicine, 557–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/174_2012_678.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Graves, Stephen, Mengshi Li, Dongyoul Lee, and Michael K. Schultz. "On the Use of 203Pb Imaging to Inform 212Pb Dosimetry for 203/212Pb Image-Guided Alpha-Particle Therapy for Cancer." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum, 277–87. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_28.

Full text
Abstract:
AbstractAlpha-emitting radiopharmaceutical therapy shows promise for improving the therapeutic efficacy of existing and future targeting ligands by limiting off-target irradiation and by preempting many cell survival mechanisms. Dosimetry-guided therapies are emerging as potentially safer and more effective than approaches based on a fixed-activity-administration paradigm. Among the candidates of alpha-emitting radionuclides, 212Pb shows promise for use under an image-guided dosimetry-informed theranostic paradigm, whereby 203Pb can be used for dosimetry and treatment planning. In this chapter, we model an approach to accurately estimate the dosimetry of 212Pb-based radiopharmaceuticals using 203Pb as a surrogate. However, uncertainties arise in dosimetric predictions for 212Pb based on 203Pb imaging due to the potential for migration of 212Pb radionuclide progeny (i.e., 212Bi, 212Po, 208Tl) from the site of 212Pb decay. On the other hand, based on distinct gamma-ray energies of the 212Pb progeny, the design of in vivo experiments is described that have the potential to define these uncertainties more precisely, so as to gain insights into the potential toxicity of bioconjugated and potentially decoupled 212Bi in tissues. The promise of alpha-particle radionuclide therapy is evidenced by a tenfold increase in publications over the last 30 years, and it is anticipated that the elementally matched 203Pb/212Pb radionuclide pair will play a key role in our progress toward personalized receptor-targeted alpha-particle therapy for cancer.
APA, Harvard, Vancouver, ISO, and other styles
5

Lawal, Ismaheel O., Alfred Morgenstern, Otto Knoesen, Mariza Vorster, Frank Bruchertseifer, and Mike M. Sathekge. "Therapy of Castration-Resistant Prostate Cancer: Where Is the Place of 225Ac-PSMA?" In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum, 255–65. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_26.

Full text
Abstract:
AbstractSince the first report in 2004 confirming the survival advantage conferred by docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), many more agents have also been found to prolong life and are now in routine use in clinical practice. Despite the multitude of these effective agents, mCRPC remains a fatal disease with a poor prognosis. Efforts to develop more effective therapies are, therefore, ongoing. Targeting prostate-specific membrane antigen (PSMA) overexpressed on prostate cancer cells has become an attractive option for mCRPC treatment. Ligands that bind to PSMA expressed on prostate cancer cells have been labeled to radionuclides for imaging and therapy in a theranostic approach to prostate cancer management. Actinium-225 (225Ac) is an alpha-emitting radionuclide that has been successfully labeled to PSMA ligands as 225Ac-PSMA for targeted alpha therapy (TAT) of mCRPC. The short path length of the highly energetic alpha particles causes deposition of massive energy in the tumor, leading to irreparable double-strand DNA damage, and consequently, tumor cell death while sparing surrounding normal tissues. When applied as a last-line therapy agent, 225Ac-PSMA therapy effectiveness is comparable or better than agents applied earlier in the treatment sequence of mCRPC. 225Ac-PSMA produces the most remarkable response in the chemotherapy-naïve setting, causing a high and sustained response in men with mCRPC. Xerostomia, a result of 225Ac-PSMA irradiation of the salivary gland parenchyma resulting from its intense accumulation in the glands, is the most worrisome complication of therapy. Different interventions, including dynamic dose de-escalation, combination therapy, and reduced administered activity, are being explored to ameliorate this adverse effect of treatment.
APA, Harvard, Vancouver, ISO, and other styles
6

Chaudhri, M. Anwar, M. Nasir Chaudhri, Qamar Nadeem, and Qaiser Jabbar. "Production of Ac-225 with Cyclotrons for Generating Bi-213 for Targeted Alpha Therapy." In IFMBE Proceedings, 686–87. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-03474-9_193.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zheng, Yifan, Yoonsuk Huh, Qianqian Su, Jiaming Wang, Yunduan Lin, Kai Vetter, and Youngho Seo. "Collimatorless Scintigraphy for Imaging Extremely Low Activity Targeted Alpha Therapy (TAT) with Weighted Robust Least Squares (WRLS)." In Medical Image Computing and Computer Assisted Intervention – MICCAI 2020, 803–11. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-59728-3_78.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nock, Berthold A., and Theodosia Maina. "Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening, and Clinical Translation." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum, 207–24. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_22.

Full text
Abstract:
AbstractCancer theranostics is an emerging and exciting field in nuclear medicine, whereby suitably designed radionuclide carriers, after injection to patients, seek and specifically interact with biomolecular targets overexpressed on cancer cells. When a diagnostic radionuclide is applied, molecular imaging with SPECT (gamma emitter) or PET (positron emitter) will reveal tumor lesions, allowing for initial diagnosis and assessment of disease spread and progression. Hence, molecular imaging represents a reliable tool for patient stratification, dosimetry and planning of therapy that follows next with the respective therapeutic radionuclide (beta, Auger electron, or alpha emitter) carrier in an integrated patient-tailored approach. In this way, patients are spared from ineffective and toxic therapies that only impair quality of life without any tangible benefit. Several recent examples have demonstrated the feasibility and efficacy of this strategy. Thus, the advent of radiolabeled somatostatin analogs in the management of neuroendocrine tumors on one hand, and the successful application of prostate-specific membrane antigen inhibitors to diagnose and combat prostate cancer on the other, are two elegant paradigms of this approach.In this chapter, we shall discuss important issues pertaining to the design and preclinical evaluation of peptide-based radioligands, focusing on compound examples developed in our center. The steps to be followed for clinical translation of selected analogs will be also briefly described. Emphasis will be given on the significance of pilot proof-of-principle studies in a small number of patients to guide further efforts toward drug development and registration.
APA, Harvard, Vancouver, ISO, and other styles
9

Schultz, Michael K., Jean-Pierre Pouget, Frank Wuest, Bryce Nelson, Jan Andersson, Sarah Cheal, Mengshi Li, et al. "Radiobiology of Targeted Alpha Therapy." In Nuclear Medicine and Molecular Imaging, 380–403. Elsevier, 2022. http://dx.doi.org/10.1016/b978-0-12-822960-6.00093-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chatterjee, Sayandev, Kenneth R. Czerwinski, Hilary A. Fitzgerald, Andrew L. Lakes, Zuolei Liao, Russell C. Ludwig, Katie M. McBride, and Vladislav P. Vlasenko. "Delivery of radiopharmaceuticals and theranostic agents: targeted alpha therapy." In Novel Platforms for Drug Delivery Applications, 349–404. Elsevier, 2023. http://dx.doi.org/10.1016/b978-0-323-91376-8.00012-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Targeted alpha therapy"

1

Huang, C., B. W. Miller, L. R. Furenlid, and M. A. Kupinski. "Simulation of SPECT Imaging for Targeted Alpha-Therapy with Surrogate." In 2024 IEEE Nuclear Science Symposium (NSS), Medical Imaging Conference (MIC) and Room Temperature Semiconductor Detector Conference (RTSD), 1. IEEE, 2024. http://dx.doi.org/10.1109/nss/mic/rtsd57108.2024.10654856.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brzezinski, K., L. Barrientos, M. Borja-Lloret, J. V. Casaña, F. Hueso-González, J. Pérez-Curbelo, A. Ros, et al. "MACACO III Compton camera for imaging of targeted alpha therapy using 225Ac." In 2024 IEEE Nuclear Science Symposium (NSS), Medical Imaging Conference (MIC) and Room Temperature Semiconductor Detector Conference (RTSD), 1–2. IEEE, 2024. http://dx.doi.org/10.1109/nss/mic/rtsd57108.2024.10655191.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tafreshi, Narges K., Nella C. Delva, Christopher J. Tichacek, Michael L. Doligalski, Darpan N. Pandya, Nikunj B. Bhatt, HyunJoo Kil, et al. "Abstract 5198: Targeted alpha particle therapy for uveal melanoma." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hasegawa, S., and HK Li. "PO-110 Targeted alpha-therapy for gastric cancer metastasized to liver in mice." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.635.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Schmidtlein, Charles Ross, Matthew K. Maroun, Andrzej Krol, Howard Gifford, Lisa Bodei, Joseph O'Donoghue, Ida Häggström, and Yuesheng Xu. "A deblurring/denoising corrected scintigraphic planar image reconstruction model for targeted alpha therapy." In Biomedical Applications in Molecular, Structural, and Functional Imaging, edited by Barjor S. Gimi and Andrzej Krol. SPIE, 2021. http://dx.doi.org/10.1117/12.2584736.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bruchertseifer, F., L. Krolicki, J. Kunikowska, H. Koziara, B. Krolicki, M. Jakucinski, D. Pawlak, A. Apostolidis, and A. Morgenstern. "Targeted alpha therapy of recurrent glia tumors: clinical experience with 225 Ac-Substance-P." In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Muath, A. M., J. Yang, K. Kim, I. Lim, and S. K. Woo. "Estimation of absorbed fraction for Ac-225 targeted alpha therapy using cortex and medulla geometry." In 2023 IEEE Nuclear Science Symposium, Medical Imaging Conference and International Symposium on Room-Temperature Semiconductor Detectors (NSS MIC RTSD). IEEE, 2023. http://dx.doi.org/10.1109/nssmicrtsd49126.2023.10338616.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tworowska, Izabela, Ebrahim S. Delpassand, Julien Torgue, Farah Shanoon, Jason Hurt, and Rodolfo Nunez. "Abstract CT159: First-in-human dose escalation of AlphaMedixTMfor targeted alpha-emitter therapy of neuroendocrine tumors." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-ct159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Eriksson, Sophie E., Erika Elgström, Sture Lindegren, and Tom Bäck. "Abstract 834: Formation of DNA double-strand breaks in colon tumors after targeted alpha therapy with211At-mAb." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-834.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hasegawa, Sumitaka, and Huizi Keiko Li. "Abstract 5343: Experimental targeted alpha-particle therapy against liver metastasis of HER2-positive gastric cancer in mice." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5343.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Targeted alpha therapy"

1

Sgouros, George. Therapy of Ovarian Carcinoma by Targeted Delivery of Alpha-Particles Using Immunoliposomes Capable of Retaining Alpha-Emitting Daughters. Fort Belvoir, VA: Defense Technical Information Center, October 2005. http://dx.doi.org/10.21236/ada448269.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sgouros, George. Therapy of Ovarian Carcinoma by Targeted Delivery of Alpha-Particles Using Immunoliposomes Capable of Retaining Alpha-Emitting Daughters. Fort Belvoir, VA: Defense Technical Information Center, October 2004. http://dx.doi.org/10.21236/ada431313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ma, Jiao, Lanyin Li, Taiping Liao, Weidong Gong, and Chunyin Zhang. Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer:a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Targeted alpha therapy' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography